Genmab — Juni 2017
-
As other sectors stumble, health care stocks are finally hitting new all-time highs again after 2 long years - https://lyonssharepro.com/2017/06/this-sector-getting-healthy-just-in-time/
-
ærgerligt tidspunkt, at vi fik alle de gode nyheder i GEN...
-
Genmab is
now slowly reacting
-
Hidsige tal i auktionen. 1.500 blev lige flashet.
-
1.441
-
Helge, ved du hvad det er der foregår i lukkeauktionen, når man nogen gange ser meget høje (eller lave) match-kurser undervejs? De holder aldrig. Men er der virkelig mennesker af kød og blod der byder så meget over/under kursen lige før luk - eller er det noget rent computerteknisk, der foregår?
-
ADCT-301 (Humax-TAC):The results seen in this early analysis are impressive for these patients with relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma have been heavily pre-treated. These data, combined with the positive results we have seen in preclinical studies continue to highlight what we believe to be the significant potential of our ADC technology platform
-
The overall response rate for evaluable patients with HL treated with doses ³30µg/kg was 38.5% while 8 of 25 (32%) efficacy evaluable patients at all dose levels with HL and NHL have achieved stable disease as their best response. ADCT-301 was well tolerated and toxicities manageable. Dose escalation continues.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind